Veri MedTech Holdings VRHI

Veri MedTech Holdings, Inc. operates as a healthcare technology company providing medical cannabis evaluation services and direct to consumer digital health platforms through its subsidiaries Veriheal and DosePop.

Veri MedTech generates revenue primarily through fees for medical marijuana card evaluations and related services offered by Veriheal and through subscription fees and telehealth consultation charges for DosePop’s direct to consumer health and wellness services. The company serves patients seeking medical cannabis authorization and consumers looking for digital health treatments for conditions such as weight loss ADHD dermatology and sexual health.

The company operates through the following segments: Veriheal and DosePop.

• Veriheal: This segment provides medical cannabis healthcare technology services including physician evaluations for medical marijuana cards state to state coverage and both online and in person consultations serving over 400,000 patients and generating over $100 million in revenue since inception.
• DosePop: This segment offers direct to consumer digital health and wellness services via a subscription based model providing telehealth consultations and prescription delivery for weight loss ADHD dermatology anti aging and sexual health treatments generating approximately $24,000 in revenue with roughly $5,000 in recurring monthly revenue.

Veri MedTech Holdings, Inc. holds a leading position in the medical cannabis healthcare technology market with Veriheal capturing approximately 5.3% of U. S. medical cannabis card approvals and providing the broadest state to state coverage among independent providers. Key competitors for Veriheal include platforms such as Leafwell and NuggMD as well as large dispensary chains that offer doctor referrals but lack the company’s national reach and integrated online experience. Veriheal’s competitive advantages stem from its proprietary HIPAA compliant platform, AI driven personalization, automated prescription fulfillment and its combination of telehealth and in person consultation services. DosePop is positioned as a high growth disruptor in the direct to consumer healthcare technology space focusing on millennial and Gen Z consumers with a stigma free brand and AI driven patient engagement. Its subscription based model and access to Veriheal’s existing patient base lower acquisition costs and increase lifetime value relative to traditional telehealth providers.

Veri MedTech Holdings, Inc. serves patients seeking medical marijuana authorizations through Veriheal and consumers seeking digital health treatments for conditions such as weight loss ADHD dermatology anti aging and sexual health through DosePop.